Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.
Read Article
The ACR has published a formal international consensus guidance on VEXAS as a resource for clinicians seeking to understand the disease and its management.
VEXAS is a rare genetic disorder; the acronym stands for Vacuoles E1 enzyme X-linked
Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast.
Read Article
The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA)
Read Article
Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.
Read Article
A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease
A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.
Read Article
Formerly classified as an ANCA-associated vasculitis, EGPA is both most commonly ANCA negative and clinically different to the other two ANCA-associated vasculitis conditions, GPA and MPA. The management of EGPA has frequently fallen into the trap of being copied from its more common and well-
Read Article
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.
A systematic review included 102
Women with antiphospholipid syndrome and lupus anti-coagulant are at high risk of developing adverse pregnancy outcomes (APO). Usual care includes low molecular weight heparin (LMWH) and low dose aspirin (LDA). Despite these therapies, APO have been reported up to 40%. An important
Read Article
Links:
Links:
Links:
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
